Status:
COMPLETED
A Pilot Study to Assess the Feasibility and Tolerability of the AccuFlow Perfusion Sensor for Intrapartum Hemorrhage
Lead Sponsor:
Megan Lord
Collaborating Sponsors:
ThermaSENSE Corp
Conditions:
Hemorrhage, Postpartum
Hemorrhage
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Obstetric hemorrhage is one of the leading causes of maternal death worldwide. One of the challenges in management of hemorrhage is that young, healthy women compensate for blood loss via peripheral v...
Detailed Description
Hemorrhage remains the leading cause of direct pregnancy-related death in both the developing world and the developed world. Young, healthy patients compensate for hemorrhage via peripheral vasoconstr...
Eligibility Criteria
Inclusion
- Age 18 years or older
- English speaking
- Undergoing planned cesarean section at Women and Infants Hospital
- BMI on admission less than or equal to 35 kg/m2
- Preoperative hemoglobin greater than or equal to 11.5g/dL on routine labs
Exclusion
- History of allergy or other adverse reaction to adhesives
- Fever at the time of recruitment
Key Trial Info
Start Date :
May 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2021
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04370639
Start Date
May 20 2020
End Date
February 28 2021
Last Update
July 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Women and Infants Hospital of Rhode Island
Providence, Rhode Island, United States, 02905